Jeff Yass’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-21,500
| Closed | -$1.2M | – | 14248 |
|
|
2025
Q4 | $1.2M | Sell |
21,500
-700
| -3% | -$36.3K | ﹤0.01% | 6768 |
|
|
2025
Q3 | $1.06M | Sell |
22,200
-5,500
| -20% | -$246K | ﹤0.01% | 7218 |
|
|
2025
Q2 | $1.12M | Buy |
27,700
+3,800
| +16% | +$153K | ﹤0.01% | 7136 |
|
|
2025
Q1 | $1.05M | Buy |
23,900
+900
| +4% | +$39.7K | ﹤0.01% | 7148 |
|
|
2024
Q4 | $989K | Buy |
23,000
+2,500
| +12% | +$114K | ﹤0.01% | 6966 |
|
|
2024
Q3 | $909K | Sell |
20,500
-400
| -2% | -$17.1K | ﹤0.01% | 7002 |
|
|
2024
Q2 | $831K | Buy |
20,900
+9,600
| +85% | +$389K | ﹤0.01% | 7022 |
|
|
2024
Q1 | $487K | Buy |
11,300
+500
| +5% | +$21.5K | ﹤0.01% | 8580 |
|
|
2023
Q4 | $449K | Sell |
10,800
-9,900
| -48% | -$375K | ﹤0.01% | 8937 |
|
|
2023
Q3 | $823K | Sell |
20,700
-1,300
| -6% | -$55K | ﹤0.01% | 7081 |
|
|
2023
Q2 | $902K | Buy |
22,000
+900
| +4% | +$37.2K | ﹤0.01% | 6925 |
|
|
2023
Q1 | $865K | Sell |
21,100
-4,100
| -16% | -$172K | ﹤0.01% | 7197 |
|
|
2022
Q4 | $1.03M | Buy |
25,200
+2,000
| +9% | +$83.3K | ﹤0.01% | 6115 |
|
|
2022
Q3 | $932K | Buy |
23,200
+2,900
| +14% | +$124K | ﹤0.01% | 6808 |
|
|
2022
Q2 | $853K | Buy |
20,300
+3,600
| +22% | +$151K | ﹤0.01% | 6914 |
|
|
2022
Q1 | $756K | Sell |
16,700
-2,200
| -12% | -$96.7K | ﹤0.01% | 7866 |
|
|
2021
Q4 | $872K | Buy |
+18,900
| New | +$895K | ﹤0.01% | 7647 |
|
|
2020
Q3 | – | Sell |
-7,800
| Closed | -$335K | – | 11241 |
|
|
2020
Q2 | $335K | Buy |
7,800
+2,200
| +39% | +$90.9K | ﹤0.01% | 8166 |
|
|
2020
Q1 | $202K | Buy |
+5,600
| New | +$239K | ﹤0.01% | 8680 |
|
|
2018
Q3 | – | Sell |
-5,600
| Closed | -$241K | – | 10377 |
|
|
2018
Q2 | $241K | Hold |
5,600
| – | – | ﹤0.01% | 8261 |
|
|
2018
Q1 | $234K | Buy |
+5,600
| New | +$244K | ﹤0.01% | 8066 |
|
|
2017
Q1 | – | Sell |
-11,000
| Closed | -$430K | – | 10124 |
|
|
2016
Q4 | $430K | Buy |
11,000
+3,500
| +47% | +$142K | ﹤0.01% | 7298 |
|
|
2016
Q3 | $331K | Buy |
+7,500
| New | +$341K | ﹤0.01% | 6769 |
|
|
2016
Q1 | – | Sell |
-4,100
| Closed | -$210K | – | 9762 |
|
|
2015
Q4 | $210K | Sell |
4,100
-700
| -15% | -$35.7K | ﹤0.01% | 8347 |
|
|
2015
Q3 | $225K | Sell |
4,800
-3,400
| -41% | -$205K | ﹤0.01% | 8528 |
|
|
2015
Q2 | $511K | Sell |
8,200
-2,800
| -25% | -$174K | ﹤0.01% | 7606 |
|
|
2015
Q1 | $679K | Buy |
+11,000
| New | +$652K | ﹤0.01% | 6551 |
|
|
2014
Q4 | – | Sell |
-8,000
| Closed | -$424K | – | 10171 |
|
|
2014
Q3 | $424K | Buy |
+8,000
| New | +$407K | ﹤0.01% | 7490 |
|
Other funds holding XPH
KWM
FCBT
EP
Jeff Yass's XPH Position: Q2 2026 in Review
Jeff Yass reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 34% in Q2 2026, selling an estimated $986K and leaving 32,012 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #6357.
Jeff Yass first reported a position in XPH in Q2 2013 and has held it in 48 quarters since. The position peaked at $19.2M in Q3 2015. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.
- Jeff Yass held 32,012 shares of State Street SPDR S&P Pharmaceuticals ETF worth $2.12M as of Q2 2026.
- Jeff Yass sold 16,822 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $986K.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6357 holding.
- Jeff Yass first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2013 and has held it in 48 quarters since.
- Jeff Yass's State Street SPDR S&P Pharmaceuticals ETF position peaked at $19.2M in Q3 2015.
- 93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.